A. Renard, R. Veth, H. Schreuder, M. Pruszczynski, J. Bokkerink et al., Osteosarcoma: Oncologic and functional results. A single institutional report covering 22 years, Journal of Surgical Oncology, vol.80, issue.3, pp.124-129, 1999.
DOI : 10.1002/(SICI)1096-9098(199911)72:3<124::AID-JSO3>3.0.CO;2-G

G. Bacci, A. Briccoli, S. Ferrari, A. Longhi, M. Mercuri et al., Neoadjuvant chemotherapy for osteosarcoma of the extremity, European Journal of Cancer, vol.37, issue.16, pp.2030-2039, 2001.
DOI : 10.1016/S0959-8049(01)00229-5

S. Rosenberg, Progress in human tumour immunology and immunotherapy, Nature, vol.411, issue.6835, pp.380-384, 2001.
DOI : 10.1038/35077246

H. Kinoshita, H. Yoshikawa, K. Shiiki, Y. Hamada, Y. Nakajima et al., Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated apoptosis by down-regulating FLIP-L expression, International Journal of Cancer, vol.73, issue.6, pp.986-991, 2000.
DOI : 10.1002/1097-0215(20001215)88:6<986::AID-IJC23>3.0.CO;2-B

X. Duan, Z. Zhou, S. Jia, M. Colvin, E. Lafleur et al., Interleukin-12 Enhances the Sensitivity of Human Osteosarcoma Cells to 4-Hydroperoxycyclophosphamide by a Mechanism Involving the Fas/Fas-Ligand Pathway, Clinical Cancer Research, vol.10, issue.2, pp.777-783, 2004.
DOI : 10.1158/1078-0432.CCR-1245-02

H. Inaba, M. Glibetic, S. Buck, Y. Ravindranath, and J. Kaplan, Interferon-? sensitizes osteosarcoma cells to fas-induced apoptosis by up-regulating fas receptors and caspase-8, Pediatric Blood & Cancer, vol.5, issue.7, pp.729-736, 2004.
DOI : 10.1002/pbc.20151

N. Labarriere, M. Pandolfino, N. Gervois, A. Khammari, M. Tessier et al., Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients, Cancer Immunology, Immunotherapy, vol.51, issue.10, pp.532-538, 2002.
DOI : 10.1007/s00262-002-0313-3

B. Dreno, J. Nguyen, A. Khammari, M. Pandolfino, M. Tessier et al., Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma, Cancer Immunology, Immunotherapy, vol.51, issue.10, pp.539-546, 2002.
DOI : 10.1007/s00262-002-0315-1

L. Worth, E. Lafleur, S. Jia, and E. Kleinerman, Fas expression inversely correlates with metastatic potential in osteosarcoma cells, Oncology Reports, vol.9, pp.823-827, 2002.
DOI : 10.3892/or.9.4.823

E. Lafleur, N. Koshkina, J. Stewart, S. Jia, L. Worth et al., Increased Fas Expression Reduces the Metastatic Potential of Human Osteosarcoma Cells, Clinical Cancer Research, vol.10, issue.23, pp.8114-8119, 2004.
DOI : 10.1158/1078-0432.CCR-04-0353

T. Imai, S. Adachi, K. Nishijo, M. Ohgushi, M. Okada et al., FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells, Oncogene, vol.22, issue.58, pp.9231-9242, 2003.
DOI : 10.1038/sj.onc.1207184

K. Watanabe, K. Okamoto, and S. Yonehara, Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP, Cell Death and Differentiation, vol.12, issue.1, pp.10-18, 2005.
DOI : 10.1038/sj.cdd.4401507

C. Yee, J. Thompson, D. Byrd, S. Riddell, P. Roche et al., Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells, Proceedings of the National Academy of Sciences, vol.99, issue.25, pp.16168-16173, 2002.
DOI : 10.1073/pnas.242600099

S. Reynolds, E. Celis, A. Sette, R. Oratz, R. Shapiro et al., HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients, J Immunol, vol.161, pp.6970-6976, 1998.

B. Thurner, I. Haendle, C. Roder, D. Dieckmann, P. Keikavoussi et al., Vaccination with Mage-3a1 Peptide???Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma, The Journal of Experimental Medicine, vol.18, issue.11, pp.1669-1678, 1999.
DOI : 10.1073/pnas.96.5.2268

O. Shea, J. Ortaldo, and J. , The biology of natural killer cells: Insights into molecular basis of function In: The Natural Killer Cell, pp.2-40, 1992.

A. Cesano and D. Santoli, Two unique human leukemic T-cell lines endowed with a stable cytotoxic function and a different spectrum of target reactivity analysis and modulation of their lytic mechanisms, In Vitro Cellular & Developmental Biology - Animal, vol.170, issue.9-10, pp.657-662, 1992.
DOI : 10.1007/BF02631041

S. Visonneau, A. Cesano, K. Jeglum, and D. Santoli, Adjuvant treatment of canine osteosarcoma with the human cytotoxic T-cell line TALL-104, Clin Cancer Res, vol.5, pp.1868-1875, 1999.

B. Kubista, K. Trieb, H. Blahovec, R. Kotz, and M. Micksche, Hyperthermia increases the susceptibility of chondro-and osteosarcoma cells to natural killer cell-mediated lysis, Anticancer Res, vol.22, pp.789-792, 2002.

C. Castelli, L. Rivoltini, F. Rini, F. Belli, A. Testori et al., Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer, Cancer Immunology, Immunotherapy, vol.53, issue.3, pp.227-233, 2004.
DOI : 10.1007/s00262-003-0481-9

K. Trieb, S. Lang, and R. Kotz, HEAT-SHOCK PROTEIN 72 IN HUMAN OSTEOSARCOMA: T-Lymphocyte Reactivity and Cytotoxicity, Pediatric Hematology and Oncology, vol.87, issue.5, pp.355-364, 2000.
DOI : 10.1080/08880010050034283

J. Banchereau and A. Palucka, Dendritic cells as therapeutic vaccines against cancer, Nature Reviews Immunology, vol.10, issue.4, pp.296-306, 2005.
DOI : 10.1007/s00262-003-0429-0

R. Steinman and M. Dhodapkar, Active immunization against cancer with dendritic cells: The near future, International Journal of Cancer, vol.94, issue.4, pp.459-473, 2001.
DOI : 10.1002/ijc.1503

J. Geiger, R. Hutchinson, L. Hohenkirk, E. Mckenna, A. Chang et al., Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells, The Lancet, vol.356, issue.9236, pp.1163-1165, 2000.
DOI : 10.1016/S0140-6736(00)02762-8

I. Kurzman, E. Macewen, and R. Rosenthal, Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin, Clin Cancer Res, vol.1, pp.1595-1601, 1995.

E. Macewen, I. Kurzman, R. Rosenthal, B. Smith, P. Manley et al., Therapy for Osteosarcoma in Dogs With Intravenous Injection of Liposome-Encapsulated Muramyl Tripeptide, JNCI Journal of the National Cancer Institute, vol.81, issue.12, pp.935-938, 1989.
DOI : 10.1093/jnci/81.12.935

I. Kurzman, F. Shi, D. Vail, and E. Macewen, Enhancement of Canine Pulmonary Alveolar Macrophage Cytotoxic Activity Against Canine Osteosarcoma Cells, Cancer Biotherapy & Radiopharmaceuticals, vol.14, issue.2, pp.121-128, 1999.
DOI : 10.1089/cbr.1999.14.121

E. Kleinerman, J. Gano, D. Johnston, R. Benjamin, and N. Jaffe, Efficacy of Liposomal Muramyl Tripeptide (CGP 19835A) in the Treatment of Relapsed Osteosarcoma, American Journal of Clinical Oncology, vol.18, issue.2, pp.93-99, 1995.
DOI : 10.1097/00000421-199504000-00001

E. Kleinerman, A. Raymond, C. Bucana, N. Jaffe, M. Harris et al., Unique histological changes in lung metastasis of osteosarcoma patients following therapy with liposomal muramyl tripeptide

G. Koukoulis, C. Patriarca, and V. Gould, Adhesion molecules and tumor metastasis, Human Pathology, vol.29, issue.9, pp.889-892, 1998.
DOI : 10.1016/S0046-8177(98)90191-5

E. Mcgary, A. Heimberger, L. Mills, K. Weber, G. Thomas et al., A fully human antimelanoma cellular adhesion molecule/MUC18 antibody inhibits spontaneous pulmonary metastasis of osteosarcoma cells in vivo, Clin Cancer Res, vol.9, pp.6560-6566, 2003.

J. Eklund and T. Kuzel, A review of recent findings involving interleukin-2-based cancer therapy, Current Opinion in Oncology, vol.16, issue.6, pp.542-546, 2004.
DOI : 10.1097/01.cco.0000142070.45097.68

R. Luksch, D. Perotti, G. Cefalo, G. Passerini, C. Massimino et al., Immunomodulation in a treatment program including pre-and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma, Tumori, vol.3, pp.263-268, 2003.

S. Nasr, J. Mckolanis, R. Pais, H. Findley, R. Hnath et al., A phase I study of interleukin-2 in children with cancer and evaluation of clinical and immunologic status during therapy. A pediatric oncology group study, Cancer, vol.23, issue.4, pp.783-788, 1989.
DOI : 10.1002/1097-0142(19890815)64:4<783::AID-CNCR2820640402>3.0.CO;2-F

E. Mariani, A. Meneghetti, A. Tarozzi, L. Cattini, and A. Facchini, Interleukin-12 Induces Efficient Lysis of Natural Killer-Sensitive and Natural Killer-Resistant Human Osteosarcoma Cells: the Synergistic Effect of Interleukin-2, Scandinavian Journal of Immunology, vol.4, issue.1, pp.618-625, 2000.
DOI : 10.1038/sj.gt.3300779

C. Liebau, H. Merk, S. Schmidt, C. Roesel, C. Karreman et al., Interleukin-12 and interleukin-18 change ICAM-I expression, and enhance natural killer cell mediated cytolysis of human osteosarcoma cells, Cytokines, Cellular & Molecular Therapy, vol.7, issue.4, pp.135-142, 2002.
DOI : 10.1080/13684730310001977

T. Okamoto, N. Yamada, T. Tsujimura, A. Sugihara, Y. Nishizawa et al., Inhibition by Interleukin-18 of the Growth of Dunn Osteosarcoma Cells, Journal of Interferon & Cytokine Research, vol.24, issue.3, pp.161-167, 2004.
DOI : 10.1089/107999004322917007

M. Honorati, S. Neri, L. Cattini, and A. Facchini, IL-17 enhances the susceptibility of U-2 OS osteosarcoma cells to NK cell lysis, Clinical and Experimental Immunology, vol.130, issue.3, pp.344-349, 2003.
DOI : 10.1016/8756-3282(94)90305-0

S. Ko, J. Cheon, C. Kao, A. Gotoh, T. Shirakawa et al., Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models, Cancer Res, vol.56, pp.4614-4619, 1996.

H. Tsuji, S. Kawaguchi, T. Wada, S. Nagoya, M. Inobe et al., Concurrent induction of T-cell activation and apoptosis of osteosarcoma cells by adenovirus-mediated B7-1/Fas chimeric gene transfer, Cancer Gene Therapy, vol.10, issue.9, pp.717-725, 2003.
DOI : 10.1038/sj.cgt.7700624

H. Xu, Y. Zhou, J. Seigne, G. Perng, M. Mixon et al., Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein, Cancer Res, vol.56, pp.2245-2249, 1996.
DOI : 10.1073/pnas.91.21.9837

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC44912

M. Kim, M. Sgagias, X. Deng, Y. Jung, T. Rikiyama et al., Apoptosis induced by adenovirus-mediated p14ARF expression in U2OS osteosarcoma cells is associated with increased Fas expression, Biochemical and Biophysical Research Communications, vol.320, issue.1, pp.138-144, 2004.
DOI : 10.1016/j.bbrc.2004.05.135

M. Nakase, M. Inui, K. Okumura, T. Kamei, S. Nakamura et al., p53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposome, Molecular Cancer Therapeutics, vol.4, issue.4, pp.53-625, 2005.
DOI : 10.1158/1535-7163.MCT-04-0196

O. Hellwinkel, J. Muller, A. Pollmann, and H. Kabisch, Osteosarcoma cell lines display variable individual reactions on wildtype p53 and Rb tumour-suppressor transgenes, The Journal of Gene Medicine, vol.73, issue.Pt 3, pp.407-419, 2005.
DOI : 10.1002/jgm.684

L. Worth, S. Jia, Z. Zhou, L. Chen, and E. Kleinerman, Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases, Clin Cancer Res, vol.6, pp.3713-3718, 2000.

E. Lafleur, S. Jia, L. Worth, Z. Zhou, L. Owen-schaub et al., Interleukin (IL)-12 and IL-12 gene transfer upregulate Fas expression in human osteosarcoma and breast cancer cells, Cancer Res, vol.61, pp.4066-4071, 2001.

T. Tamura, T. Nishi, T. Goto, H. Takeshima, Y. Ushio et al., Combination of IL-12 and IL-18 of electro-gene therapy synergistically inhibits tumor growth, Anticancer Res, vol.23, pp.1173-1179, 2003.

C. Liebau, C. Roesel, S. Schmidt, C. Karreman, J. Prisack et al., Immunotherapy by gene transfer with plasmids encoding IL-12/IL-18 is superior to IL- 23/IL-18 gene transfer in a rat osteosarcoma model, Anticancer Res, vol.24, pp.2861-2867, 2004.

M. Edelstein, M. Abedi, J. Wixon, and R. Edelstein, Gene therapy clinical trials worldwide 1989???2004???an overview, The Journal of Gene Medicine, vol.6, issue.6, pp.597-602, 2004.
DOI : 10.1002/jgm.619

S. Nagano, K. Yuge, M. Fukunaga, Y. Terazaki, H. Fujiwara et al., Gene therapy eradicating distant disseminated micro-metastases by optimal cytokine expression in the primary lesion only: Novel concepts for successful cytokine gene therapy, International Journal of Oncology, vol.24, pp.549-558, 2004.
DOI : 10.3892/ijo.24.3.549

W. Gu, A. Ogose, H. Kawashima, M. Ito, T. Ito et al., High-Level Expression of the Coxsackievirus and Adenovirus Receptor Messenger RNA in Osteosarcoma, Ewing's Sarcoma, and Benign Neurogenic Tumors among Musculoskeletal Tumors, Clinical Cancer Research, vol.10, issue.11, pp.3831-3838, 2004.
DOI : 10.1158/1078-0432.CCR-03-0345

H. Graat, P. Wuisman, V. Van-beusechem, J. Carette, W. Gerritsen et al., Coxsackievirus and Adenovirus Receptor Expression on Primary Osteosarcoma Specimens and Implications for Gene Therapy with Recombinant Adenoviruses, Clinical Cancer Research, vol.11, issue.6, pp.2445-2447, 2005.
DOI : 10.1158/1078-0432.CCR-04-2375

O. Feugeas, N. Guriec, A. Babin-boilletot, L. Marcellin, P. Simon et al., Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma., Journal of Clinical Oncology, vol.14, issue.2, pp.467-472, 1996.
DOI : 10.1200/JCO.1996.14.2.467

A. Witlox, V. Van-beusechem, B. Molenaar, H. Bras, G. Schaap et al., Conditionally Replicative Adenovirus with Tropism Expanded towards Integrins Inhibits Osteosarcoma Tumor Growth in Vitro and in Vivo, Clinical Cancer Research, vol.10, issue.1, pp.61-67, 2004.
DOI : 10.1158/1078-0432.CCR-0609-03

S. Raper, N. Chirmule, F. Lee, N. Wivel, A. Bagg et al., Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer, Molecular Genetics and Metabolism, vol.80, issue.1-2, pp.148-158, 2003.
DOI : 10.1016/j.ymgme.2003.08.016

R. Pellinen, T. Hakkarainen, T. Wahlfors, K. Tulimaki, A. Ketola et al., Cancer cells as targets for lentivirus-mediated gene transfer and gene therapy, International Journal of Oncology, vol.25, pp.1753-1762, 2004.
DOI : 10.3892/ijo.25.6.1753

A. Ketola, A. Maatta, T. Pasanen, K. Tulimaki, and J. Wahlfors, Osteosarcoma and chondrosarcoma as targets for virus vectors and herpes simplex virus thymidine kinase/ganciclovir gene therapy, International Journal of Molecular Medicine, vol.13, pp.705-710, 2004.
DOI : 10.3892/ijmm.13.5.705

J. Yannelli and J. Wroblewski, On the road to a tumor cell vaccine: 20 years of cellular immunotherapy, Vaccine, vol.23, issue.1, pp.97-113, 2004.
DOI : 10.1016/j.vaccine.2003.12.036

S. Ben-efraim, Cancer immunotherapy: hopes and pitfalls: a review, Anticancer Res, vol.16, pp.3235-3240, 1996.

Y. Ogihara, K. Takeda, T. Yanagawa, and Y. Hirasawa, Spontaneous regression of lung metastases from osteosarcoma, Cancer, vol.3, issue.10, pp.2798-2803, 1994.
DOI : 10.1002/1097-0142(19941115)74:10<2798::AID-CNCR2820741009>3.0.CO;2-2

J. Sabate, J. Llauger, S. Torrubia, S. Amores, and T. Franquet, Osteosarcoma of the abdominal wall with spontaneous regression of lung metastases., American Journal of Roentgenology, vol.171, issue.3, pp.691-692, 1998.
DOI : 10.2214/ajr.171.3.9725297

Y. Nabeta, S. Kawaguchi, H. Sahara, H. Ikeda, Y. Hirohashi et al., Recognition by cellular and humoral autologous immunity in a human osteosarcoma cell line, Journal of Orthopaedic Science, vol.8, issue.4, pp.554-559, 2003.
DOI : 10.1007/s00776-003-0663-5

S. Slovin, R. Lackman, S. Ferrone, P. Kiely, and M. Mastrangelo, Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype, and specificity, J Immunol, vol.137, pp.3042-3048, 1986.

Y. Sato, Y. Nabeta, T. Tsukahara, Y. Hirohashi, R. Syunsui et al., Detection and Induction of CTLs Specific for SYT-SSX-Derived Peptides in HLA-A24+ Patients with Synovial Sarcoma, The Journal of Immunology, vol.169, issue.3, pp.1611-1618, 2002.
DOI : 10.4049/jimmunol.169.3.1611

B. Worley, L. Van-den-broeke, T. Goletz, C. Pendleton, E. Daschbach et al., Antigenicity of fusion proteins from sarcomaassociated chromosomal translocations, Cancer Res, vol.61, pp.6868-6875, 2001.

H. Hsu, D. Lacey, C. Dunstan, I. Solovyev, A. Colombero et al., Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand, Proceedings of the National Academy of Sciences, vol.96, issue.7, pp.3540-3545, 1999.
DOI : 10.1073/pnas.96.7.3540

D. Lacey, E. Timms, H. Tan, M. Kelley, C. Dunstan et al., Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation, Cell, vol.93, issue.2, pp.165-176, 1998.
DOI : 10.1016/S0092-8674(00)81569-X

W. Simonet, D. Lacey, C. Dunstan, M. Kelley, M. Chang et al., Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density, Cell, vol.89, issue.2, pp.309-319, 1997.
DOI : 10.1016/S0092-8674(00)80209-3

E. Tsuda, M. Goto, S. Mochizuki, K. Yano, F. Kobayashi et al., Isolation of a Novel Cytokine from Human Fibroblasts That Specifically Inhibits Osteoclastogenesis, Biochemical and Biophysical Research Communications, vol.234, issue.1, pp.137-142, 1997.
DOI : 10.1006/bbrc.1997.6603

H. Yasuda, N. Shima, N. Nakagawa, K. Yamaguchi, M. Kinosaki et al., Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL, Proceedings of the National Academy of Sciences, vol.95, issue.7, pp.3597-3602, 1998.
DOI : 10.1073/pnas.95.7.3597

E. Grimaud, L. Soubigou, S. Couillaud, P. Coipeau, A. Moreau et al., Receptor Activator of Nuclear Factor ??B Ligand (RANKL)/Osteoprotegerin (OPG) Ratio Is Increased in Severe Osteolysis, The American Journal of Pathology, vol.163, issue.5, pp.2021-2031, 2003.
DOI : 10.1016/S0002-9440(10)63560-2

L. Hofbauer, C. Dunstan, T. Spelsberg, B. Riggs, and S. Khosla, Osteoprotegerin Production by Human Osteoblast Lineage Cells Is Stimulated by Vitamin D, Bone Morphogenetic Protein-2, and Cytokines, Biochemical and Biophysical Research Communications, vol.250, issue.3, pp.776-781, 1998.
DOI : 10.1006/bbrc.1998.9394

L. Hofbauer, F. Gori, B. Riggs, D. Lacey, C. Dunstan et al., Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis, Endocrinology, vol.140, issue.10, pp.4382-4389, 1999.
DOI : 10.1210/en.140.10.4382

P. Bhatia, R. Leach, and G. Roodman, Loss of RANKL, a TNF-alpha ligand family member, in sporadic osteosarcoma, J Bone Miner Res, vol.14, issue.1, p.37, 1999.

Y. Wittrant, S. Theoleyre, C. Chipoy, M. Padrines, F. Blanchard et al., OPG: new therapeutic targets in bone tumours and associated osteolysis, Biochim Biophys Acta, vol.1704, pp.49-57, 2004.
URL : https://hal.archives-ouvertes.fr/inserm-00669006

P. Honore, N. Luger, M. Sabino, M. Schwei, S. Rogers et al., Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord, Nat Med, vol.6, pp.521-528, 2000.

B. Wong, R. Josien, S. Lee, B. Sauter, H. Li et al., TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell???specific Survival Factor, The Journal of Experimental Medicine, vol.372, issue.12, pp.2075-2080, 1997.
DOI : 10.1084/jem.183.1.7

D. Anderson, E. Maraskovsky, W. Billingsley, W. Dougall, M. Tometsko et al., A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function, Nature, vol.390, issue.6656, pp.175-179, 1997.
DOI : 10.1038/36593

J. Emery, P. Mcdonnell, M. Burke, K. Deen, S. Lyn et al., Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL, Journal of Biological Chemistry, vol.273, issue.23, pp.14363-14367, 1998.
DOI : 10.1074/jbc.273.23.14363

R. Nyambo, N. Cross, J. Lippitt, I. Holen, G. Bryden et al., Human Bone Marrow Stromal Cells Protect Prostate Cancer Cells From TRAIL-Induced Apoptosis, Journal of Bone and Mineral Research, vol.107, issue.Suppl, pp.1712-1721, 2004.
DOI : 10.1359/JBMR.040703

D. Heymann, B. Ory, F. Gouin, J. Green, and F. Redini, Bisphosphonates: new therapeutic agents for the treatment of bone tumors, Trends in Molecular Medicine, vol.10, issue.7, pp.337-343, 2004.
DOI : 10.1016/j.molmed.2004.05.007

J. Sanders, S. Ghosh, J. Chan, G. Meints, H. Wang et al., Quantitative Structure???Activity Relationships for ???? T Cell Activation by Bisphosphonates, Journal of Medicinal Chemistry, vol.47, issue.2, pp.375-384, 2004.
DOI : 10.1021/jm0303709